PolyPid (PYPD) Q2 FY26 earnings call

PolyPid experienced a transformative quarter, marked by the FDA's acceptance of the D-PLEX100 NDA with Priority Review and the establishment of a strategic commercialization partnership with Azurity Pharmaceuticals. These milestones, coupled with robust manufacturing readiness and planned EMA submission, significantly strengthen the company's financial position and accelerate the path to market for D-PLEX100, while also enabling pipeline expansion through the Kynatrix technology.